For instance, SOX2 is credited to catalyzing pro-survival and anti-apoptotic signaling in diverse range of cancers, such as SOX2 expression develops resistance to commonly used drugs in lung cancer (e.g. erlotinib, cisplatin, paclitaxel) by suppressing pro-apoptotic BH3-only genes, namely BIM and BMF (Rothenberg et al., 2015) and through activation of oncogenic EGFR and BCL2L1 signaling (Chou et al., 2013). Here, SOX2 is linked to lung carcinoma.